|
1. Available at: http://diabetes.niddk.nih.gov/dm/pubs/statistics/index.htm. Accessed September 29, 2006.
2. Ramasamy R, Vannucci SJ, Yan SS, et al. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology. 2005 Jul;15(7):16R-28R.
3. Opara EC. Oxidative stress, micronutrients, diabetes mellitus and its complications. J R Soc Health. 2002 Mar;122(1):28-34.
4. Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature. 2006 Apr 13;440(7086):944-8.
5. Available at: http://www.alz.org/AboutAD/statistics.asp. Accessed September 29, 2006.
6. Grundman M, Thal LJ. Treatment of Alzheimer's disease: rationale and strategies. Neurol Clin. 2000 Nov;18(4):807-28.
7. Mayeux R, Sano M. Treatment of Alzheimer's disease. N Engl J Med. 1999 Nov 25;341(22):1670-9.
8. Wenk GL. Neuropathological changes in Alzheimer's disease: potential targets for treatment. J Clin Psychiatry. 2006;67 Suppl 3:3-7;quiz 23.
9. Masters CL, Cappai R, Barnham KJ, Villemagne VL. Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeteutics. J Neurochem. 2006 Jun;97(6):1700-25.
10. Moreira PI, Smith MA, Zhu X, et al. Oxidative stress and neurodegeneration. Ann NY Acad Sci. 2005 Jun;1043:545-52.
11. Available at: http://www.alz.org/icad/newsreleases/071606_noon_diabtesandad.asp. Accessed September 29, 2006.
12. Ott A, Stolk RP, van HF, et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology. 1999 Dec 10;53(9):1937-42.
13. Luchsinger JA, Tang MX, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology. 2004 Oct 12;63(7):1187-92.
14. Fishel MA, Watson GS, Montine TJ, et al. Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults. Arch Neurol. 2005 Oct;62(10):1539-44.
15. Available at: http://www.webmd.com/content/article/5/1680_51079.htm. Accessed September 29, 2006.
16. Rivellese AA, Lilli S. Quality of dietary fatty acids, insulin sensitivity and type 2 diabetes. Biomed Pharmacother. 2003 Mar;57(2):84-7.
17. [No authors listed]. Monograph. Fish oil. Altern Med Rev. 2000 Dec;5(6):576-80.
18. Kelly GS. Insulin resistance: lifestyle and nutritional interventions. Altern Med Rev. 2000 Apr;5(2):109-32.
19. Watson GS, Reger MA, Baker LD, et al. Effects of exercise and nutrition on memory in Japanese Americans with impaired glucose tolerance. Diabetes Care. 2006 Jan;29(1):135-6.
20. Rodriguez-Moran M, Guerrero-Romero F. Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: a randomized double-blind controlled trial. Diabetes Care. 2003 Apr;26(4):1147-52.
21. Anderson RA, Cheng N, Bryden NA, et al. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes. 1997 Nov;46(11):1786-91.
22. Jacob S, Ruus P, Hermann R, et al. Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. Free Radic Biol Med. 1999 Aug;27(3-4):309-14.
23. Arivazhagan P, Panneerselvam C. Alpha-lipoic acid increases Na+K+ATPase activity and reduces lipofuscin accumulation in discrete brain regions of aged rats. Ann N Y Acad Sci. 2004 Jun;1019:350-4.
24. Lovell MA, Xie C, Xiong S, Markesbery WR. Protection against amyloid beta peptide and iron/hydrogen peroxide toxicity by alpha lipoic acid. J Alzheimers Dis. 2003 Jun;5(3):229-39.
25. Khan A, Safdar M, li Khan MM, Khattak KN, Anderson RA. Cinnamon improves glucose and lipids of people with type 2 diabetes. Diabetes Care. 2003 Dec;26(12):3215-8.
26. Boldyrev AA, Stvolinsky SL, Tyulina OV, et al. Biochemical and physiological evidence that carnosine is an endogenous neuroprotector against free radicals. Cell Mol Neurobiol. 1997 Apr;17(2):259-271.
27. Wang AM, Ma C, Xie ZH, Shen F. Use of carnosine as a natural anti-senescence drug for human beings. Biochemistry (Mosc.). 2000 Jul;65(7):869-71.
28. Stvolinskii SL, Fedorova TN, Yuneva MO, Boldyrev AA. Protective effect of carnosine on Cu,Zn-superoxide dismutase during impaired oxidative metabolism in the brain in vivo. Bull Exp Biol Med. 2003 Feb;135(2):130-2.
29. Dukic-Stefanovic S, Schinzel R, Riederer P, Munch G. AGES in brain ageing: AGE-inhibitors as neuroprotective and anti-dementia drugs? Biogerontology. 2001;2(1):19-34.
30. Hipkiss AR, Preston JE, Himswoth DT, Worthington VC, Abbot NJ. Protective effects of carnosine against malondialdehyde-induced toxicity towards cultured rat brain endothelial cells. Neurosci Lett. 1997 Dec 5;238(3):135-8.
31. Preston JE, Hipkiss AR, Himsworth DT, Romero IA, Abbott JN. Toxic effects of beta-amyloid(25-35) on immortalised rat brain endothelial cell: protection by carnosine, homocarnosine and beta-alanine. Neurosci Lett. 1998 Feb 13;242(2):105-8.
32. Singh S, Khar A. Biological effects of curcumin and its role in cancer chemoprevention and therapy. Anticancer Agents Med Chem. 2006 May;6(3):259-70.
33. Pari L, Murugan P. Effect of tetrahydrocurcumin on blood glucose, plasma insulin and hepatic key enzymes in streptozotocin induced diabetic rats. J Basic Clin Physiol Pharmacol. 2005;16(4):257-74.
34. Jain SK, Rains J, Jones K. Effect of curcumin on protein glycosylation, lipid peroxidation, and oxygen radical generation in human red blood cells exposed to high glucose levels. Free Radic Biol Med. 2006 Jul 1;41(1):92-6.
35. Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL. A potential role of the curry spice curcumin in Alzheimer's disease. Curr Alzheimer Res. 2005 Apr;2(2):131-6.
36. Takeuchi M, Kikuchi S, Sasaki N, et al. Involvement of advanced glycation end-products (AGEs) in Alzheimer's disease. Curr Alzheimer Res. 2004 Feb;1(1):39-46.
37. Furber JD. Extracellular glycation crosslinks: prospects for removal. Rejuvenation Res. 2006 Summer;9(2):274-8.
38. Munch G, Kuhla B. Luth HJ, Arendt T, Robinson SR. Anti-AGEing defenses against Alzheimer's disease. Biochem Soc Trans. 2003 Dec;31(Pt 6):1397-9.
39. Peppa M, Uribarri J, Vlassara H. Glucose, advanced glycation end products, and diabetes complications: what is new and what works. Clinical Diabetes. 2003;21:186-7.
40. McCarty MF. The low-AGE content of low-fat vegan diets could benefit diabetics - though concurrent taurine supplementation may be needed to minimize endogenous AGE production. Med Hypotheses. 2005;64(2):394-8.
41. Qian P, Cheng S, Guo J, Niu Y. Effects of vitamin E and vitamin C on nonenzymatic glycation and peroxidation in experimental diabetic rats. Wei Sheng Yan Jiu. 2000 Jul;29(4):226-8.
42. Thomas MC, Baynes JW, Thorpe SR, Cooper MF. The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. Curr Drug Targets. 2005 Jun;6(4):453-74.
43. Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimers Dis. 2005 Dec;8(3):247-68.
44. de la Monte SM, Tong M, Lester-Coll N, Plater M Jr, Wands JR. Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: Relevance to Alzheimer's disease. J Alzheimers Dis. 2006 Nov;10(1):89-109. |